DiaMedica Therapeutics Inc.DMAC
Market cap
$375.66M
P/E ratio
| Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Research and development | 5 | 8 | 8 | 9 | 8 | 13 | 19 |
| General and administrative | 3 | 4 | 4 | 5 | 6 | 8 | 8 |
| Total operating expenses | 7 | 12 | 13 | 14 | 14 | 21 | 27 |
| Operating loss | -7 | -12 | -13 | -14 | -14 | -21 | -27 |
| Other income, net | -0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Total other income, net | 1 | 1 | 0 | 0 | 0 | 2 | 2 |
| Loss before income tax expense | - | - | - | -14 | -14 | -19 | -24 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net loss | -6 | -11 | -12 | -14 | -14 | -19 | -24 |
| Unrealized gain on marketable securities | - | 0 | -0 | -0 | -0 | 0 | 0 |
| Comprehensive loss | - | -11 | -12 | -14 | -14 | -19 | -24 |
| Basic and diluted net loss per share (in dollars per share) | - | - | - | - | -0.52 | -0.6 | -0.6 |